Benzocyclooctene-based and indene-based anticancer agents
AssigneeBaylor University
InventorsKevin G. PINNEY, Christine A. HERDMAN, Rajendra P. TANPURE, Zhi CHEN
Life of this patent
Estimating the term…
Abstract
Benzocyclooctene (fused 6,8 ring system) analogues and corresponding indene (fused 6,5 ring system) analogues function as inhibitors of tubulin polymerization. The compounds are useful as anticancer agents in a new therapeutic approach for cancer treatment utilizing small-molecule inhibitors of tubulin polymerization that also act as vascular disrupting agents (VDAs).
Claims17
A benzocyclooctene compound demonstrating inhibition of tubulin polymerization and having a structure of:
- wherein
- A is a bond, C═O, C═NH, or C═NR1, where R1 is any alkyl, aryl, or alkaryl substituent;
- B is CH2, NH, O, S, CH—OH, or CH—OR2, wherein R2 is CH3, or PO3−, or C-Z, wherein Z is halogen;
- and
- D is CH, N, C—OH, or C—OR3, wherein R3 is CH3, any alkyl substituent, any alkoxy substituent, any alkyl or alkoxy substituent including heteroatoms, any carbonyl substituent, any ester substituent, or PO3−, or C-Z, wherein Z is halogen.
An indene compound demonstrating inhibition of tubulin polymerization and having a structure of:
- wherein
- A is a bond, C═O, C═NH, or C═NR1, where R1 is any alkyl, aryl, or alkaryl substituent;
- B is CH2, NH, O, S, CH—OH, or CH—OR2, wherein R2 is CH3, or PO3−, or C-Z, wherein Z is halogen;
- and
- D is CH, N, C—OH, or C—OR3, wherein R3 is CH3, any alkyl substituent, any alkoxy substituent, any alkyl or alkoxy substituent including heteroatoms, any carbonyl substituent, any ester substituent, or PO3−, or C-Z, wherein Z is halogen, and wherein at least one D is C—OH or C—OPO32−.
Dependencies are inferred from the claim text.